A “remarkable” new drug that outperforms the best treatments currently available should become the first choice for patients with heart failure, according to research.
Clinical trials were stopped early because of the promise shown by the new medication.
Research on more than 8,000 patients found that the experimental drug saved 20 per cent more lives than existing “gold standard” treatments.
Experts in Barcelona for the European Cardiology Society congress said the new compound, LCZ696, was “a major advance” in the treatment of a “terrible problem”.
Heart failure occurs when the heart has been damaged – for example, by a heart attack – and can no longer pump blood around the body as well as it once did.